HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  van Poelgeest, Mariette I E ^a   Welters, Marij J P ^a   van Esch, Edith M G ^a   Stynenbosch, Linda F M ^a   Kerpershoek, Gijs ^a   van Meerten, Els L van Persijn ^a   van den Hende, Muriel ^a   Löwik, Margriet J G ^a   Berends van der Meer, Dorien M A ^a   Fathers, Lorraine M ^a   Valentijn, A Rob P M ^a   Oostendorp, Jaap ^a   Fleuren, Gert Jan ^a   Melief, Cornelis J M ^a,b   Kenter, Gemma G ^a,c   van der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISA Pharmaceuticals   (Netherlands)

^c Center of Gynaecologic Oncology Amsterdam   (Netherlands)

Author keywords

Cervical cancer; HPV; Immunomonitoring; Immunotherapy; Survival; Synthetic long peptides; Therapeutic vaccine

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HPV16 SYNTHETIC LONG PEPTIDE VACCINE; INTERLEUKIN 10; INTERLEUKIN 5; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN; SUBUNIT VACCINE; WART VIRUS VACCINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONCENTRATION LOSS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEMALE GENITAL TRACT CANCER; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE ULCER; MIDDLE AGED; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; RASH; RIGOR; SKIN SWELLING; SKIN TINGLING; SURVIVAL TIME; VOMITING; CELL PROLIFERATION; FEMALE GENITAL TRACT TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; RECURRENT DISEASE; REGRESSION ANALYSIS; UTERINE CERVIX TUMOR; VIROLOGY; CLINICAL TRIAL; GENITAL NEOPLASMS, FEMALE; PROCEDURES; UTERINE CERVICAL NEOPLASMS;

ADULT; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CYTOKINES; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; RECURRENCE; REGRESSION ANALYSIS; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; VACCINES, SUBUNIT;

EID: 84875689800     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-88     Document Type: Article

References (46)

1. Pisani P, Bray F, Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002, 97:72-81
2. Larson DM, Copeland LJ, Stringer CA, Gershenson DM, Malone JM Jr, Edwards CL: Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 1988, 30:381-387
3. Burke TW, Hoskins WJ, Heller PB, Shen MC, Weiser EB, Park RC: Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma. Obstet Gynecol 1987, 69:382-385
4. Zur Hausen H: Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996, 1288:F55-F78
5. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796-802
6. Cannistra SA, NiloffJM: Cancer of the uterine cervix. N Engl J Med 1996, 334:1030-1038
7. Koutsky L: Epidemiology of genital human papillomavirus infection. Am J Med 1997, 102:3-8
8. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell G: Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995, 171:1026-1030
9. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428
10. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265
11. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632
12. Matloubian M, Concepcion RJ, Ahmed R: CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994, 68:8056-8063
13. van der Burg SH, Arens R, Melief CJ: Immunotherapy for persistent viral infections and associated disease. Trends Immunol 2011, 32:97-103
14. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH: High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007, 67:354-361
15. Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, Melief CJ, Hellebrekers BW, Fleuren GJ, Kenter GG, et al: Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and-DP as a restriction element. Int J Cancer 2008, 122:486-494
16. van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, et al: Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 2007, 104:12087-12092
17. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH: Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004, 64:5449-5455
18. van der Burg SH, Melief CJ: Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol 2011, 23:252-257
19. Heusinkveld M, Welters MJ, van Poelgeest MI, van der Hulst JM, Melief CJ, Fleuren GJ, Kenter GG, van der Burg SH: The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer 2011, 128:379-389
20. Moore DH: Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 2008, 6:53-57
21. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004, 22:3113-3119
22. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005, 23:4626-4633
23. Long HJ 3rd: Management of metastatic cervical cancer: review of the literature. J Clin Oncol 2007, 25:2966-2974
24. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009, 27:4649-4655
25. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ: Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002, 169:350-358
26. Vambutas A, Devoti J, Nouri M, Drijfhout JW, Lipford GB, Bonagura VR, Burg SH, Melief CJ: Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005, 23:5271-5280
27. Welters MJ, Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH: Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 2007, 25:1379-1389
28. Melief CJ, van der Burg SH: Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008, 8:351-360
29. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, der Meer DM B-V, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, et al: Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008, 14:178-187
30. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, der Meer DM B-V, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, et al: Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008, 14:169-177
31. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, der Meer DM B-V, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847
32. Welters MJ, Kenter GG, van Steenwijk PJ DV, Lowik MJ, Berends-van Der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, et al: Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010, 107:11895-11899
33. Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, et al: T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. Immunity 2012, 37:1-2
34. Singh SK, Meyering M, Ramwadhdoebe TH, Stynenbosch LF, Redeker A, Kuppen PJ, Melief CJ, Welters MJ, van der Burg SH: The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunol Immunother 2012, 61:1953-1963
35. van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A: Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 2011, 3:108-144
36. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010, 102:1388-1397
37. Lesterhuis WJ, de Vries IJ, Aarntzen EA, de Boer A, Scharenborg NM, van de Rakt M, van Spronsen DJ, Preijers FW, Figdor CG, Adema GJ, Punt CJ: A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer 2010, 103:1415-1421
38. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G: The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008, 118:1991-2001
39. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjanen KJ, Cunha-Filho JS: Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression-clinicopathological correlation. Gynecol Oncol 2007, 105:157-165
40. Heusinkveld M, van Steenwijk PJ DV, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, van Hall T, van der Burg SH: M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 2011, 187:1157-1165
41. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268
42. Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, Kapiteijn E, Gelderblom H, Nijman HW, Valentijn AR, et al: Addition of interferon-.alpha; to the p53-SLPW vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer 2013 Apr 1; 132(7):1581-91
43. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, Melief CJ, van der Burg SH: Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009, 15:6341-6347
44. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454
45. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, Fleuren GJ: Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients? Clin Cancer Res 2008, 14:2028-2035
46. Menetrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W: Targeting regulatory T cells. Target Oncol 2012, 7:15-28